Search Results for: Global Cancer Vaccine Market to

Articles

- 2/1/2011

Ligand Pharmaceuticals Forms Drug Development Alliance With Chiva PharmaceuticalsLigand Pharmaceuticals, Inc. recently announced it has entered into a strategic relationship...

- 1/10/2012

Particle Sciences Expands Program With Additional Proprietary Modeling Capabilities Particle Sciences recently announced it has added a third computational module...

- EXECUTIVE INTERVIEW – Viral Gene: Protein-Targeting Cancer Vaccine Could Boost Survival Rates

Harry A. Arena, MBA, President & CEO of TDT, Chris Kim, President & General Counsel, Viral Gene, Inc., and Dr. Scott Waldman, Professor & Chair of Sidney Kimmel Medical College’s Department of Pharmacology & Experimental Therapeutics at Thomas Jefferson University, discuss the unique characteristics of the vaccine, the patients who will benefit the most, and how a research team captured the attention of investors.

- INTRADERMAL DELIVERY – Advances in Intradermal Drug Delivery

Zach Marks, MS, RPh, believes efficiency of vaccine use will be critical as the world population continues to grow and vaccine prices continue to rise, and ID administration can help reduce dose cost while potentially improving immunogenicity in traditional and hard-to-treat populations.

- 9/12/2012

Cobra Biologics & Algeta Sign Monoclonal Antibody Agreement Cobra Biologics Ltd and Algeta ASA recently announced a new contract manufacturing...

- THERAPEUTIC FOCUS – New Therapeutics for Aggressive Brain Cancers

Jeffrey Bacha, MBA, says glioblastoma is one of the most common and fatal brain cancers, and new therapies to treat this disease are urgently needed. New approaches, such as vaccines and immunotherapies, have promising results, and to be most effective, will need to be used in combination with a chemotherapeutic.

- Are Mega M&As Back in Pharma?

According to Frost & Sullivan, the pharmaceutical industry is witnessing a new wave of mergers and acquisitions activities, especially mega...

- 11/15/2011

Lundbeck & Otsuka Enter Long-Term CNS Agreement, Deal Has $1.8-Billion Potential Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S recently...

- 8/22/2012

United Drug Acquires Leading Clinical Trials Materials Business United Drug plc recently announced it has reached an agreement to acquire...

- 11/8/2011

Gateway Analytical Growth Demands Move to a Larger Facility Gateway Analytical recently announced the company will move to a larger...

- J&J Expects More Than 10 NDAs

Johnson & Johnson recently announced it is developing what could eventually be game-changing treatments for depression and pain, and it's...